---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-117681"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:01:28.112295+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics reports Q3 2022 net loss of $15.1M, up from $11.1M YoY

## Summary
- Net loss $15.1M in Q3 2022 vs $11.1M in Q3 2021; R&D expenses $12.1M.
- Cash and equivalents $78.3M at Sept 30, 2022; plus $1.3M R&D incentive receivable.
- Enrolled first patient in Part C of DisTinGuish study (GEA) and DeFianCe study (CRC).
- Presented updated DKN-01 clinical data at ESMO and SITC meetings.

## SEC filing metadata
- accession: 0001104659-22-117681
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465922117681/0001104659-22-117681-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465922117681/tm2230251d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-117681
- JSON: https://secwatch.observer/filing/0001104659-22-117681.json
- Plain text: https://secwatch.observer/filing/0001104659-22-117681.txt

## Key facts
- Earnings Releases
  CYPHERPUNK TECHNOLOGIES INC. reported the third quarter ended September 30, 2022 results: net income $15.1 million.
  - Period: the third quarter ended September 30, 2022
  - Net income: $15.1 million
  - Result: reported results
  source text: Net Loss was $15.1 million for the third quarter 2022, compared to $11.1 million for the three months ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1509745/000110465922117681/0001104659-22-117681-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.